Video Case Solution: Glomus Jugulare
Read the case description and watch the video online at http://www.practicalneurology.com/videos.asp?f=video15.
The most likely cause of the left tongue atrophy in this case is:
1. Carotid dissection
2. Parsonage turner syndrome
3. Cavernous sinus pathology
4. Retroorbital pathology
5. Glomus Jugulare
Glomus Jugulare
- Hearing impairment, vocal cord paralysis, tongue deviation, and facial pain suggest involvement of the 8th, 10th, 12th, and 5th cranial nerves. Among the mentioned choices, glomus jugulare is the only one that can be that extensive.
- Glomus Jugulare is a neuroendocrine neoplasm. 97% are benign.
- It originates from paraganglia in chromaffin negative glomus cells that are derived from embryonic neural crest. 75% are sporadic, asymptomatic or causes painless masses.
- Common sites are head and neck and mostly it originates in the middle ear and spreads to the jugular foramen and beyond leading to multiple compressive cranial neuropathies.
- It is a slowly evolving tumor that appears at age 40-70 years
- Symptoms usually start with tinnitus, conductive hearing loss, and as it progresses it leads to vertigo, nystagmus,
and facial palsy. - Jugular foramen symptoms:
- 9th and 10th: dysphonia, dysphagia,
- 11th: weak trapezius and sternocleidomastoid muscle.
- 12th: tongue hemiatrophy
- Carotid canal: Horner’s syndrome
- 5th and 6th cranial nerves symptoms indicate inoperability.
- Radiation surgery usually leads to a cure or long term control
- Carotid dissection may lead to hypoglossal palsy but does not extend to the abducens or trigeminal nerve
- Cavernous Sinus pathology may lead to involvement of the 3-5th cranial nerves but does not extend to the hypoglossal nerve
- Retrorbital pathology does not go that far either.
- Parsonage turner may cause hypoglossal neuropathy but does not affect the rest of the cranial nerves.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- MAY-JUN 2025 ISSUE
Non-Botulinum Toxin Injections for Headache: Current Evidence
Chaouki Khoury, MD, MS; Nicolas P. Saikali, MDChaouki Khoury, MD, MS; Nicolas P. Saikali, MD - MAY-JUN 2025 ISSUE
Headache & Migraine: Tailored Treatments to Maximize Outcomes
Jennifer Williams McVige, MDJennifer Williams McVige, MD - MAY-JUN 2025 ISSUE
Optimizing the Transition from Pediatric to Adult Care in Headache Medicine
Allyson B. Bazarsky, DO, MS; Arthur Zayne Washington III, MDAllyson B. Bazarsky, DO, MS; Arthur Zayne Washington III, MD - MAY-JUN 2025 ISSUE
Intravenous Treatment of Headache at Outpatient Infusion Centers
Laszlo Mechtler, MD, FAAN, FEAN, FASN, FAHS; Joseph Hirtreiter, RNLaszlo Mechtler, MD, FAAN, FEAN, FASN, FAHS; Joseph Hirtreiter, RN